Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Institut de Recherches Internationales Servier
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment at 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, double-blind, placebo-controlled, with paroxetine (20 mg/day with potential progressive blinded adjustment to 40 mg/day) as validator, 3-arm parallel groups, international multicenter study
To confirm the efficacy of agomelatine (25-50 mg/day p.o.) compared to placebo after a 12-week orally treatment in non-depressed out-patients suffering from Generalized Anxiety Disorder.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (IRIS)
MAJ Il y a 4 ans
A placebo-controlled, proof-of concept study of the efficacy of gevokizumab subcutaneously over 24 weeks in the treatment of patients with polymyositis or dermatomyositis disease
The objective of this study is to evaluate the efficacy and safety of gevokizumab in adult patients with polymyositis or dermatomyositis intolerant or resistant or dependent to systemic oral corticost...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (France)
MAJ Il y a 4 ans
Evaluation of efficacy and clinical benefit of agomelatine in patients with major depressive disorder compared to serotonin-norepinephrine reuptake inhibitor (SNRI)
Not provided at time of registration and not expected to be available in the future
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (France)
MAJ Il y a 4 ans
Long-term effects of strontium ranelate on knee osteoarthritis symptoms: a two year prospective, randomised, placebo-controlled study
Not provided at time of registration and not expected to be available in the future
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (France)
MAJ Il y a 4 ans
A study to determine the maintenance of efficacy of agomelatine to prevent relapse in out-patients with major depressive disorder. A 8 to 10 weeks open period treatment with agomelatine followed by 24 weeks randomised double-blind period, placebo-controlled, parallel groups and 20 weeks of optional double-blind treatment period
Not provided at time of registration and not expected to be available in the future
Pays
Australia
,
Finland
,
France
,
South Africa
,
United Kingdom
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Efficacy of gevokizumab in the treatment of patients with Behcet`s disease uveitis Efficacia di gevokizumab nel trattamento di pazienti affetti da malattia di Behçet
The objective of this study is to demonstrate the superiority of gevokizumab as compared to placebo on top of current standard of care in reducing the risk of Behçet’s disease uveitis exacerbations ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
A study to determine the maintenance of efficacy of agomelatine (25 mg to 50 mg) to prevent relapse in out-patients with Major Depressive Disorder. A 8 to 10 weeks open period treatment with agomelatine (25 mg to 50 mg) followed by 24 weeks randomised double-blind period, placebo-controlled, parallel groups and 20 weeks of optional double-blind treatment period
To assess the efficacy of agomelatine (25 mg/50 mg), in the prevention of depressive relapse, in ambulatory patients suffering from Major Depressive Disorder, during 24 weeks of treatment after an ini...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (France)
MAJ Il y a 4 ans
Efficacy and safety of agomelatine given orally compared to placebo, in addition to a mood stabiliser in bipolar I patients with a current major depressive episode. An eight week randomised, double-blind, controlled, parallel group study followed by a double-blind extension treatment period up to one year
Not provided at time of registration and not expected to be available in the future
Pays
France
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Institut de Recherches Internationales Servier (France)
MAJ Il y a 4 ans
Effect of agomelatine on cerebral activity measured by functional magnetic resonance imaging (MRI) in patients with major depressive disorder in comparison to healthy volunteers
Not provided at time of registration and not expected to be available in the future
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of 2 g per day of strontium ranelate versus alendronate 70 mg per week in women with postmenopausal osteoporosis on bone geometry and bone strength measured by peripheral-Quantitative Computed Tomography (p-QCT)
To assess the effects of strontium ranelate in comparison with alendronate (both treatment with calcium and vitamin D supplement) on the bone geometry and bone strength in postmenopausal osteoporotic ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
5
6
7
8
9
10
11
12
13
14
Suivant